- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03098784
Nanoparticles Emitted by Aircraft Engines, Impact on Respiratory Function (NPAF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Air traffic is increasing, raising concern about local pollution and its adverse health effects on the people living in the vicinity of large airports. However, the highest risk is probably occupational exposure due to proximity. Jet exhaust is one of the main concerns at an airport and may have a health impact, particularly on the respiratory tract. Current studies are neither numerous enough nor strong enough to prove this kind of association. Yet, more and more people work in airports, and occupational exposure to jet exhaust is a fact. In 1999, the effect of occupational exposure to aircraft fuel and jet exhaust on pulmonary function and respiratory symptoms in Birmingham International Airport (Birmingham, UK) workers was reported. This work suggested that there was a link between high occupational exposure to aviation fuel or jet exhaust and excess respiratory tract symptoms, consistent with the presence of a respiratory irritant. It was a cross-sectional survey using a questionnaire filled out by the participants themselves. Respiratory and immunological function assessments and an exhaled carbon monoxide measurement were conducted with male full-time airport workers classified into three groups according to their exposure level.
The study will be presented to the volunteering subjects during an occupational medical appointment concerning their company. The information letter will be provided as well as the informed consent form to be filled for the study. Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
Method details:
- Survey: The survey breaks down into 2 parts, with a total of 94 items. The first part bears on the employees' respiratory health condition, essentially grounded on the validated EGEA survey. The rest focuses on employees' lifestyle habits, both professionally (outdoor and indoor working time, trade, type of exposure, etc.) and personally (geographical situation of the home, type of town or community, heating system, usual mode of cooking, etc.). The survey is anonymised and the answers are automatically read by datascan process.
- Spirometry: This method allows a non-invasive, simple and repeatable assessment of the respiratory function. It is indispensable to clearly explain the process to the patient. The patient sits with his or her back straight during the process. Once the subject and the device are ready, the subject deeply breathes in to fill the lungs then fully expires into the spirometer. Then the subject breathes in fully and forcedly in order to obtain the inspiratory curve. The spirometry results are compared with theoretical or predicted values determined based on patient's age, gender, size and ethnic group. Consequently, according to the subject's breathing speed and force intensity, measurements of vital capacity (VC) or forced vital capacity (FVC) are obtained. The curves will allow the other variables to be deduced, such as maximum expiratory volume per second (MEVS) or peak expiratory flow (PEF), or mean expiratory flows (MEF 25-75).
- Exhaled CO measurement (confounding factors of the respiratory function, in order to reflect the smoking status):the employee blows into the device's single-use cardboard mouthpiece after a deep inspiration followed by a fifteen-second apnea computed by the device. The measurement in part per million (ppm) is immediately displayed on the device to quantify the severity of CO intoxication. This measurement is simple and repeatable.
- Exhaled air condensate:for EAC acquisition. In fact, the RTube device is well adapted to non-invasion collection on the companies' sites. It will be used according to the recommendations from the American Thoracic Society and the EuropeanRespiratory Society. The R tube will be pre-treated as in the first study (intensive washing in order to abate background noise) and "white" R tubeswill be collected all through the study to check the method's detection limit. Briefly, the collection with nose blocked lasts for 15 minutes during which the subject breathes normally through the device. The mouth is rinsed with water before collection and the subject is asked to refrain from drinking or eating during the previous hour. This will allow ca. 1.4 ml to be collected (mean EACvolume collected during the first study over a 15-minute breathing time).
- Metrology:as this is a recent subject, there is no consensus so far on the most representative unit of measurement for employee exposure. Similarly, no current device allows all parameters to be obtained:quantitative data (particle content/cm3, sieve distribution, developed surface area of the alveolar fraction likely to be exposed in the breathing apparatus) and qualitative data (morphology, aggregation/agglomeration status, listof constitutive chemical elements). These experts' surveys require the implementation of different equipment. The method is based on personal metrology, use of portable and individual systems, as well as fixed installation metrology, organised into a single sampling by means of a cane to which the various measuring instruments are connected (Condensation ParticleCounter, ElectrostaticLow Pressure Impactor, Scanning MobilityParticleSizer, FastMobilityParticleSizer, Nanometer Surface Area Monitor, Alveolar Sensor, Alveolar Inhalable Thoracic sensor).An independent counter (Condensation ParticleCounter) allows background evolution to be monitored. Membrane sensors (such as the Giliansampling pump with membrane support) will also complement the process. They will be used as portable systems, on the employees involved in the study. Finally, the samples will be analysed by means of a SEM (Scanning Electron Microscope),model 5500 from Hitachi, associated with an energy-dispersive EDX system (X analysis system - Noranmodel from the Thermocompany).
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject must be given free and informed consent and signed the consent
- Subject must be affiliated or beneficiary in a health insurance plan
Exclusion Criteria:
- Subject has a cons-indication (or an incompatible combination therapy) for the realization of the EFR
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Air France employees working near runways
Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. Intervention: Exposure to aircraft exhaust |
The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.
These people are subject to direct exposure to exhaust from aircraft engines.
|
Air France employees working inside
Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. Intervention: Non exposure to aircraft exhaust |
The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.
These people are not subject to direct exposure to exhaust from aircraft engines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The quantity of nanoparticules present in exhaled air condensate
Time Frame: 1 day (Day of inclusion (D0)
|
The quantity of nanoparticules present in exhaled air condensate
|
1 day (Day of inclusion (D0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exhaled CO measurement
Time Frame: 1 day (Day of inclusion (D0)
|
Exhaled CO measurement
|
1 day (Day of inclusion (D0)
|
Exhaled NO measurement
Time Frame: 1 day (Day of inclusion (D0)
|
Exhaled NO measurement
|
1 day (Day of inclusion (D0)
|
Exhaled air condensate
Time Frame: 1 day (Day of inclusion (D0)
|
Exhaled air condensate
|
1 day (Day of inclusion (D0)
|
oxidative stress marker (8 isoprostane)
Time Frame: 1 day (Day of inclusion (D0)
|
oxidative stress marker (8 isoprostane)
|
1 day (Day of inclusion (D0)
|
plasma mass spectrometry which allows the simultaneous assaying of 17 elements
Time Frame: 1 day (Day of inclusion (D0)
|
plasma mass spectrometry which allows the simultaneous assaying of 17 elements (Zn, Al, Ti, Co, Cu, Zr, Ni, Cr, Ga, In, Mn, Fe, Se, Cd, Ge, Be)
|
1 day (Day of inclusion (D0)
|
Lung function
Time Frame: 1 day (Day of inclusion (D0)
|
Spirometry value
|
1 day (Day of inclusion (D0)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: NICOLAS MOLINARI, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 8755
- 2011-A00646-35 (Other Identifier: RCB number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Function
-
Centre Hospitalier Metropole SavoieCompletedRespiratory FunctionFrance
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)RecruitingRespiratory Complication | Respiratory Function LossUnited States
-
University Medical Center NijmegenOrion Corporation, Orion PharmaCompletedRespiratory Muscle FunctionNetherlands
-
Mayo ClinicRecruitingRespiratory Complication | Respiratory Function LossUnited States
-
Cairo UniversityCompletedNeonatal Respiratory FunctionEgypt
-
Federal University of Mato GrossoCompletedRespiratory Function Tests
-
Tel-Aviv Sourasky Medical CenterUnknownInadequate or Impaired Respiratory Function
-
Cliniques universitaires Saint-Luc- Université...CompletedSpirometry | Respiratory Function TestsBolivia
-
Yaron Har-ShaiUnknownBreast Reconstruction | Respiratory FunctionIsrael
-
University Hospital, GrenobleUnknownCardiac Function | Respiratory Function | Life ExperiencesFrance
Clinical Trials on Exposure to aircraft exhaust
-
Novosibirsk City Hospital #2Siberian Branch of the Russian Academy of Medical SciencesCompletedChronic Obstructive Pulmonary DiseaseRussian Federation
-
University of EdinburghUmeå UniversityCompletedCoronary Heart DiseaseSweden
-
Umeå UniversityCompletedHealthy | Exposure to PollutionSweden
-
University of British ColumbiaOttawa Hospital Research Institute; Government of AlbertaCompleted
-
Umeå UniversityUniversity of EdinburghCompleted
-
Umeå UniversityCompleted
-
Universidad Politecnica de MadridUnknown
-
University of AthensRecruitingAtherosclerosisGreece
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | Weight Gain | Food PreferencesUnited States
-
AlyatecCompletedAllergic Rhinitis | Rhinoconjunctivitis | Allergy to PollenFrance